Mogamulizumab Q4week Dosing in Participants With R/R CTCL

NCT04745234 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous T-Cell Lymphoma, Relapsed
Cutaneous T-Cell Lymphoma Refractory

Interventions

DRUG: Mogamulizumab

Sponsor

Kyowa Kirin, Inc.